Idiopathic Purpura Fulminans Associated With Anti-PS Antibodies in Children

Idiopathic Purpura Clinical Trial

Official title:

Idiopathic Purpura Fulminans Associated With Anti-PS Antibodies in Children: a French Multicenter Retrospective Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04845113
• Other study ID #: RECHMPL21_0234
• Status: Completed
• Start date: January 1, 2021
• Est. completion date: July 31, 2021

Study information

• Verified date: October 2021
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Idiopathic purpura fulminans by anti-protein S antibody is a very rare but potentially extremely serious entity. The data in the literature are poor with only isolated report boxes and a single series of less than 10 boxes. The creation of a larger series of cases would make it possible to better understand this pathology and to offer assistance in diagnosis and management.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: July 31, 2021
• Est. primary completion date: July 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion criteria:

• diagnostic of idiopathic purpura fulminans

• Acquired protein S deficiency

Exclusion criteria:

• Other infecious purpura diagnosis

Related Conditions & MeSH terms

• Idiopathic Purpura
• Purpura
• Purpura Fulminans
• Purpura, Thrombocytopenic, Idiopathic

Locations

Country	Name	City	State
France	Uhmontpellier	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of anti-protein S antibody	Rate of anti-protein S antibody	1 day